drugset
drugset / Trial / NCT06255340

A Study in Healthy Men to Test How Different Doses of BI 3031185 Are Tolerated and How Food Influences the Amount of BI 3031185 in the Blood

NCT06255340 ↗

Phase 1 Completed 75 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

This trial starts the clinical development of BI 3031185. The single rising dose (SRD) part of the trial investigates safety, tolerability, and pharmacokinetics of a range of single doses of BI 3031185 as basis for further development. The food effect (FE) part is conducted to assess the effect of food on the relative bioavailability of the BI 3031185 tablet formulation.

Timeline

Start
2024-03-11
Primary completion
2024-08-28
Completion
2024-08-28

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 3031185 Unknown — Oral

Indications

No indication recorded.